AR067056A1 - Compuesto de espiroindolina, sal farmaceuticamente aceptable del mismo, composicion que lo comprende y su uso para preparar un medicamento - Google Patents
Compuesto de espiroindolina, sal farmaceuticamente aceptable del mismo, composicion que lo comprende y su uso para preparar un medicamentoInfo
- Publication number
- AR067056A1 AR067056A1 ARP080102605A ARP080102605A AR067056A1 AR 067056 A1 AR067056 A1 AR 067056A1 AR P080102605 A ARP080102605 A AR P080102605A AR P080102605 A ARP080102605 A AR P080102605A AR 067056 A1 AR067056 A1 AR 067056A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- independently
- alkoxy
- hydroxy
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Un compuesto de espiroindolina de la siguiente formula (1), o una de sus sales farmacéuticamente aceptable o uno de sus enantiomeros; en la que cada R1 es independientemente halogeno, CF3, alquilo C1-4, alcoxi C1-4, OCF3, CN, alquil C1-6-C(O)-NH-, alquil C1-6NH-C(O)-, -CH2-N(R7)2, -CH2-O-R8, C1-4S(O)r-, COOH o heteroarilo; R2 es H, alquilo C1-4, -CH2C(O)OR9 o CH2C(O)N(R9)2; cada R3 es independientemente alquilo C1-6 o hidroxi-alquilo C1-6 cada R4 es independientemente OH, F, CI, CN, alquilo C1-4, hidroxi-alquilo C1-4, o alcoxi C1-4, Y es-NH-o como el resto de formula (2); R5 es H, OH, F, CI, CN, CF3, alquilo C1-6, hidroxi-alquilo C1-6 o alcoxi C1-6; cada R6 es independientemente halogeno, CF3, alquilo C1-4, alcoxi C1-4, OCF3, benciloxi o CN; cada R7 es independientemente H, alquilo C1-4 o junto con el átomo de nitrogeno al que están unidos, forman un grupo heterocicloalquilo de 5 o 6 miembros; R8 es H, alquilo C1-6, bencilo o fenilo; cada R9 es independientemente H, alquilo C1-6 o bencilo; cada R10 es independientemente OH, F, CI, CN, alquilo C1-4, hidroxi-alquilo C1-4 o alcoxi C1-4, n es 0, 1 o 2; m es 0, 1, 2 o 3; p es 0, 1 o2; q es 0, 1 o2; r es 0, 1 o 2; y s es 0, 1 o 2. La sal de benzoato de dicho compuesto. Composicion que lo comprende y uso de dicho compuesto para preparar un medicamento util para el tratamiento de enfermedades asociadas con la sobreexpresion de CCR2, tales como aterosclerosis, dolor inflamatorio, influenza, síndrome metabolico, esclerosis multiple, asma, enfermedad renal, insuficiencia cardiaca congestiva, enfermedad de Alzheimer, accidente cerebrovascular, enfermedad de Crohn, enfermedad inflamatoria del intestino, endometriosis o diabetes.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94514707P | 2007-06-20 | 2007-06-20 | |
| US4315608P | 2008-04-08 | 2008-04-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR067056A1 true AR067056A1 (es) | 2009-09-30 |
Family
ID=40137143
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080102605A AR067056A1 (es) | 2007-06-20 | 2008-06-19 | Compuesto de espiroindolina, sal farmaceuticamente aceptable del mismo, composicion que lo comprende y su uso para preparar un medicamento |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US7723350B2 (es) |
| EP (1) | EP2166848A4 (es) |
| JP (1) | JP5341076B2 (es) |
| AR (1) | AR067056A1 (es) |
| CL (1) | CL2008001810A1 (es) |
| PE (1) | PE20090829A1 (es) |
| TW (1) | TW200904423A (es) |
| UY (1) | UY31162A1 (es) |
| WO (1) | WO2008157741A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102015708B (zh) * | 2008-01-09 | 2014-03-26 | 阵列生物制药公司 | 作为akt蛋白激酶抑制剂的嘧啶基环戊烷 |
| EP2370423A4 (en) * | 2008-12-04 | 2012-05-30 | Glaxo Group Ltd | PROCESS FOR PREPARING A SPIROINDOLINE AND A PREVENT Therefor |
| WO2010093578A1 (en) * | 2009-02-10 | 2010-08-19 | Glaxo Group Limited | Indolinyl-, benzofuranyl-, and benzothienyl- amides as modulators of chemokine receptors |
| US8563722B2 (en) | 2009-02-24 | 2013-10-22 | Glaxo Group Limited | Stereoselective hydrogenation of a ketone |
| AU2011212478B2 (en) | 2010-02-05 | 2014-11-06 | Intervet International B.V. | Spiroindoline Compounds For Use as Anthelminthics |
| WO2013017678A1 (en) | 2011-08-04 | 2013-02-07 | Intervet International B.V. | Novel spiroindoline compounds |
| US10503774B2 (en) * | 2012-01-27 | 2019-12-10 | Koninklijke Philips N.V. | Medical selection system |
| EP2881391A1 (en) | 2013-12-05 | 2015-06-10 | Bayer Pharma Aktiengesellschaft | Spiroindoline carbocycle derivatives and pharmaceutical compositions thereof |
| EP3570893A1 (en) | 2017-01-17 | 2019-11-27 | GlaxoSmithKline Intellectual Property Development Ltd | Non peptidic heterobivalent molecules for treating inflammatory diseases |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5962462A (en) | 1996-12-13 | 1999-10-05 | Merck & Co., Inc. | Spiro-substituted azacycles as modulators of chemokine receptor activity |
| WO1998025605A1 (en) * | 1996-12-13 | 1998-06-18 | Merck & Co., Inc. | Spiro-substituted azacycles as modulators of chemokine receptor activity |
| CA2278309A1 (en) * | 1997-01-21 | 1998-07-23 | Merck & Co., Inc. | 3,3-disubstituted piperidines as modulators of chemokine receptor activity |
| JP2001278886A (ja) * | 2000-03-28 | 2001-10-10 | Dai Ichi Seiyaku Co Ltd | ベンゾオキサジン誘導体及びこれを含有する医薬 |
| GB0107907D0 (en) * | 2001-03-29 | 2001-05-23 | Smithkline Beecham Plc | Novel compounds |
| SE0202133D0 (sv) * | 2002-07-08 | 2002-07-08 | Astrazeneca Ab | Novel compounds |
| WO2004041279A1 (en) * | 2002-10-30 | 2004-05-21 | Merck & Co., Inc. | Gamma-aminoamide modulators of chemokine receptor activity |
| CA2546147A1 (en) * | 2003-12-23 | 2005-07-14 | Arena Pharmaceuticals, Inc. | Novel spiroindoline or spiroisoquinoline compounds, methods of use and compositions thereof |
| EP1802602A1 (en) * | 2004-09-28 | 2007-07-04 | Janssen Pharmaceutica N.V. | Substituted dipiperdine ccr2 antagonists |
| CN101227903A (zh) | 2005-06-02 | 2008-07-23 | 詹森药业有限公司 | 用作orl-1受体调节剂的新型3-螺环吲哚基衍生物 |
| US20070197590A1 (en) * | 2006-01-31 | 2007-08-23 | Demong Duane E | Substituted dipiperidine ccr2 antagonists |
| EP2190286A4 (en) * | 2007-08-14 | 2011-06-01 | Glaxo Group Ltd | SPIROINDENES AND SPIROINDANES AS MODULATORS OF CHEMOKINE RECEPTORS |
| JP2011500590A (ja) * | 2007-10-11 | 2011-01-06 | グラクソ グループ リミテッド | ケモカイン受容体のモジュレータとしてのピペリジニルヒドロキシエチルピペリジン誘導体 |
| WO2009061881A1 (en) | 2007-11-07 | 2009-05-14 | Glaxo Group Limited | Spirodihydrobenzofurans as modulators of chemokine receptors |
| ES2414159T3 (es) * | 2008-06-23 | 2013-07-18 | Janssen Pharmaceutica, N.V. | Antagonistas de acrilamida piperidilo de CCR2 |
-
2008
- 2008-06-18 UY UY31162A patent/UY31162A1/es unknown
- 2008-06-18 PE PE2008001039A patent/PE20090829A1/es not_active Application Discontinuation
- 2008-06-18 CL CL2008001810A patent/CL2008001810A1/es unknown
- 2008-06-18 TW TW097122652A patent/TW200904423A/zh unknown
- 2008-06-19 AR ARP080102605A patent/AR067056A1/es unknown
- 2008-06-20 US US12/142,899 patent/US7723350B2/en active Active
- 2008-06-20 US US12/665,335 patent/US8431590B2/en active Active
- 2008-06-20 WO PCT/US2008/067589 patent/WO2008157741A1/en not_active Ceased
- 2008-06-20 JP JP2010513425A patent/JP5341076B2/ja active Active
- 2008-06-20 EP EP08771538A patent/EP2166848A4/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP2166848A4 (en) | 2011-08-03 |
| JP5341076B2 (ja) | 2013-11-13 |
| US20080318990A1 (en) | 2008-12-25 |
| JP2010530886A (ja) | 2010-09-16 |
| CL2008001810A1 (es) | 2008-12-26 |
| UY31162A1 (es) | 2008-11-28 |
| PE20090829A1 (es) | 2009-07-25 |
| EP2166848A1 (en) | 2010-03-31 |
| US20110034499A1 (en) | 2011-02-10 |
| WO2008157741A1 (en) | 2008-12-24 |
| US7723350B2 (en) | 2010-05-25 |
| TW200904423A (en) | 2009-02-01 |
| US8431590B2 (en) | 2013-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR067056A1 (es) | Compuesto de espiroindolina, sal farmaceuticamente aceptable del mismo, composicion que lo comprende y su uso para preparar un medicamento | |
| CY1118973T1 (el) | Παραγωγα αμιδιου βενζοϊμιδαζολο-καρβοξυλικου οξεος για τη θεραπεια μεταβολικων ή καρδιαγγειακων νοσηματων | |
| EA201391158A1 (ru) | Диаминиевые соли фенотиазина и их применение | |
| AR079260A1 (es) | Inhibidores de bencimidazol de la produccion de leucotrienos, un procedimiento para su preparacion, composiciones farmaceuticas que los comprenden y su empleo como medicamentos en el tratamiento de trastornos mediados por leucotrienos | |
| PE20090159A1 (es) | COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs | |
| JOP20130256B1 (ar) | مركبات سلفامويل اريل اميدات واستعمالها كمواد علاجية لمعالجة التهاب الكبد نوع بي | |
| ME02766B (me) | Derivati arilmetoksi izoindolina i kompozicije koje ih obuhvataju i postupci njihove primene | |
| AR083849A1 (es) | Antagonistas de mdm2 de espiro-oxindol | |
| CL2014003181A1 (es) | Compuestos derivados de benzamidas n- sustituidas o piridinamidas n-sustituidas; composicion farmaceutica que los comprende; metodo de tratamiento; y su uso para el tratamiento de enfermedades o trastornos seleccionados de dolor, depresion y enfermedades cardiovasculares, respiratorias o psiquiatricas o combinaciones de estas. | |
| EA201001682A1 (ru) | Производные фенил- и бензодиоксинилзамещенных индазолов | |
| HRP20171028T1 (hr) | Indolski i indazolski spojevi koji aktiviraju ampk | |
| HRP20170638T1 (hr) | MODULATORI RETINOIDNIMA SRODNOG SIROČETA RECEPTORA γ (ROR-γ), NAMIJENJENI UPOTREBI U LIJEČENJU AUTOIMUNIH I PROTUUPALNIH BOLESTI | |
| AR088175A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas utiles para tratar cancer y composiciones farmaceuticas que las contienen | |
| AR083872A1 (es) | Derivados de acido carbamoil-cicloalquil-acetico sustituidos como inhibidores de nep | |
| MY169986A (en) | Benzimidazole-proline derivatives | |
| EA201492285A1 (ru) | Соединения n-алкилтриазола в качестве антагонистов лизофосфатидной кислоты (lpar) | |
| EA201001585A1 (ru) | Производные тиенопиридона в качестве активаторов амр-активированной протеинкиназы (амрк) | |
| AR066095A1 (es) | Compuesto de oxadiazol su uso para preparar un medicamento composicion farmaceutica que lo comprende y procedimiento para prepararla | |
| PE20080281A1 (es) | COMPUESTOS CINAMIDA COMO INHIBIDORES DE LA SINTESIS DEL ß-AMILOIDE 40 Y 42 | |
| JP2016506935A5 (es) | ||
| AR060489A1 (es) | Derivados del acido benzoazepin - oxi- acetico como agonistas de ppar - delta usados para aumentar hdl- c, reducir ldl-c y reducir colesterol | |
| AR058065A1 (es) | Compuestos de carboxiamina y uso de los mismos.composiciones farmaceuticas. | |
| RU2014149183A (ru) | Проницаемые ингибиторы гликозидазы и их применения | |
| BR112015006436A2 (pt) | novas piridinonas bicíclicas | |
| AR069796A1 (es) | Derivados de bencimidazol, sustituido por carboxilo o por hidroxilo, proceso para prepararlos y composiciones farmaceuticas que los contienen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |